Document Detail


Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients--a preliminary study.
MedLine Citation:
PMID:  21967833     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND PURPOSE: The aim of the present study was to investigate whether administration of edaravone during t-PA infusion can enhance early recanalization in acute stroke patients.
METHODS: This trial was undertaken as a multicenter, single blind, randomized, open-labeled study. Acute stroke patients with M1 or M2 occlusion within 3h of onset were studied prospectively. The subjects were randomly allocated to edaravone (Edaravone group: when t-PA was intravenously infused, intravenous edaravone (30 mg) was started at the same time) and no edaravone (Non-Edaravone group). Early recanalization within 1h after t-PA infusion and neurological recovery 24h after t-PA infusion were compared between the two groups.
RESULTS: 40 patients (23 men, 17 women; mean age, 76.4 ± 8.2 years, median 79 years) were enrolled; 23 patients were assigned to the Edaravone group and 17 to the Non-Edaravone group. Early recanalization was more frequently observed in the Edaravone group than in the Non-Edaravone group (56.5% vs. 11.8%, P=0.0072). Eight patients who underwent endovascular therapy immediately after t-PA infusion were excluded, and neurological recovery was analyzed. Remarkable and good recoveries were more frequently observed in the Edaravone group than in the Non-Edaravone group (80.1% vs. 45.5%, P=0.0396).
CONCLUSION: Early recanalization and good neurological recovery were more frequently observed in the Edaravone group than in the Non-Edaravone group. These results demonstrate that administration of edaravone during t-PA infusion should enhance early recanalization in acute stroke patients.
Authors:
Kazumi Kimura; Juya Aoki; Yuki Sakamoto; Kazuto Kobayashi; Kenichi Sakai; Takeshi Inoue; Yasuyuki Iguchi; Kensaku Shibazaki
Related Documents :
20970173 - A randomized prospective controlled study for assessment of different ureteral occlusio...
4217303 - Effects of population size and selection intensity on responses to disruptive selection...
17976843 - Outcomes of elderly heart failure recipients of icd and crt.
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial     Date:  2011-10-02
Journal Detail:
Title:  Journal of the neurological sciences     Volume:  313     ISSN:  1878-5883     ISO Abbreviation:  J. Neurol. Sci.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-10     Completed Date:  2012-09-20     Revised Date:  2013-08-28    
Medline Journal Info:
Nlm Unique ID:  0375403     Medline TA:  J Neurol Sci     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  132-6     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier B.V. All rights reserved.
Affiliation:
Department of Stroke Medicine, Kawasaki Medical School, Japan. kimurak@med.kawasaki-m.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Antipyrine / administration & dosage,  analogs & derivatives*
Female
Free Radical Scavengers / administration & dosage*
Humans
Infusions, Intravenous
Male
Prospective Studies
Recovery of Function / drug effects,  physiology
Single-Blind Method
Stroke / drug therapy*,  metabolism,  physiopathology
Time Factors
Tissue Plasminogen Activator / administration & dosage*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Free Radical Scavengers; 60-80-0/Antipyrine; EC 3.4.21.68/Tissue Plasminogen Activator; S798V6YJRP/phenylmethylpyrazolone
Comments/Corrections
Comment In:
J Neurol Sci. 2013 Aug 15;331(1-2):177   [PMID:  23711751 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia wh...
Next Document:  Peroxidation of lipoproteins in multiple sclerosis.